The representation displayed is that of cyclin-dependent kinase 2 (CDK2) as the protein. The ligand pictured is the oxindole inhibitor, 4-(5-bromo-2-oxo-2h-indol-3-ylazo)- benzenesulfonamide. CDK2 is part of the Ser/Thr protein kinases. CDK2 is a positive regulator of the eukaryotic cell cycle progression and is a catalytic unit that helps the cell progress from G1 to S.
In the study “The Structure of Cyclin-Dependent Kinase 2 (CDK2) in Complex with an Oxindole Inhibitor” researchers studied whether using a topical oxindole inhibitor would reduce the chemotherapy-induced alopecia (CIA). Alopecia is characterized by hair loss. By inhibiting the CDK2, the cell cycle is slowed and the sensitivity to the epithelium from many cell cycle-active antitumor agents is reduced.
The CDK2 is composed of a total of 7 alpha-helices and 6 beta-sheets. The can be seen here.
This presentation of the protein-ligand module shows the in which the oxindole inhibitor interacts with CDK2. The oxindole inhibitor interacts with CDK2 throught the Asp86A, ILe10A, Phe80A, and Leu83A amino acids on CDK2